Seroconversion of HBsAg in HBeAg positive and HBeAg negative patients with chronic HBV treated with entecavir: A case series

European Review for Medical and Pharmacological Sciences

Volumn 14, Issue 6, 2010, Pages 551-554

  D'Ettorre, Gabriella ^a   Barbarini, G ^b   Corti, F ^c   Gobber, M ^d   Pastecchia, C ^e   Ricci, G L ^a   Siciliano, M ^f   Annicchiarico, B E ^f   Vullo, V ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c Versilia Hospital   (Italy)

^d ASL Vercelli   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f CATHOLIC UNIVERSITY   (Italy)

Author keywords

Entecavir; HBV infection; Seroconversion

Indexed keywords

ADEFOVIR DIPIVOXIL; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; PEGINTERFERON ALPHA2A; ANTIVIRUS AGENT; GUANINE;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; ASTHENIA; CASE STUDY; CLINICAL ARTICLE; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEPATITIS B; HUMAN; MALE; MUSCULOSKELETAL PAIN; SEROCONVERSION; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; BLOOD; HEPATITIS B, CHRONIC; IMMUNOLOGY; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 77955801583     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. DELANEY WE 4TH, BORROTO-ESODA K. Therapy of chronic hepatitis B: trends and developments. Curr Opin Pharmacol 2008; 8: 532-540.
2. EASL JURY: EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol 2003; 38: 533-540.
3. ANDERSSON KL, CHUNG RT. Monitoring during and after antiviral therapy for hepatitis B. Hepatology 2009; 49(5 Suppl): S166-S173.
4. CHEVALIEZ S, PAWLOTSKY JM. Diagnosis and management of chronic viral hepatitis: antigens, antibodies and viral genomes. Best Pract Res Clin Gastroenterol 2008; 22: 1031-1048.
5. LOK AS, MCMAHON BJ. Chronic hepatitis B. Hepatology 2001; 34: 1225-1241.
6. PERRILLO R. Benefits and risks of interferon therapy for hepatitis B. Hepatology 2009; 49(5 Suppl): S103-S111.
7. CHENG PN, CHANG TT. Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients. Expert Rev Anti Infect Ther 2008; 6: 569-579.
8. GISH RG, LOK AS, CHANG TT, DE MAN RA, GADANO A, SOLLANO J, HAN KH, CHAO YC, LEE SD, HARRIS M, YANG J, COLONNO R, BRETT-SMITH H. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 1437-1444. (Pubitemid 350029745)
9. CHANG TT, GISH RG, DE MAN R, GADANO A, SOLLANO J, CHAO YC, LOK AS, HAN KH, GOODMAN Z, ZHU J, CROSS A, DEHERTOGH D, WILBER R, COLONNO R, APELIAN D; BEHoLD AI463022 STUDY GROUP. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-1010.
10. LAI CL, SHOUVAL D, LOK AS, CHANG TT, CHEINOUER H, GOODMAN Z, DEHERTOGH D, WILBER R, ZINK RC, CROSS A, COLONNO R, FERNANDES L; BEHoLD AI463027 STUDY GROUP. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-1020.
11. CHIEN RN, LIAW YF. Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success. Best Pract Res Clin Gastroenterol 2008; 22: 1081-1092.
12. SHERMAN M, YURDAYDIN C, SIMSEK H, SILVA M, LIAW YF, RUSTGI VK, SETTE H, TSAI N, TENNEY DJ, VAUGHAN J, KRETER B, HINDES R; AI463026 BENEFITS OF ENTECAVIR FOR HEPATITIS B LIVER DISEASE (BEHoLD) STUDY GROUP. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008; 48: 99-108.
13. YUAN Y, ILOEJE UH, HAY J, SAAB S. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. J Manag Care Pharm 2008; 14: 21-33.